Mark Wildgust, The Janssen Pharmaceutical Companies of Johnson and Johnson, shared a post on X:
“Looking forward to sharing the story of how the Johnson and Johnson Innovative Medicine team working in partnership with the medical community, Saad Z. Usmani Marivi Mateos Byoung Chul Cho, has been at the forefront of innovation in developing bispecifics in oncology.
More posts featuring Johnson and Johnson Innovative Medicine.